The protective effects of baicalin for respiratory diseases: an update and future perspectives

Background: Respiratory diseases are common and frequent diseases. Due to the high pathogenicity and side effects of respiratory diseases, the discovery of new strategies for drug treatment is a hot area of research. Scutellaria baicalensis Georgi (SBG) has been used as a medicinal herb in China for over 2000 years. Baicalin (BA) is a flavonoid active ingredient extracted from SBG that BA has been found to exert various pharmacological effects against respiratory diseases. However, there is no comprehensive review of the mechanism of the effects of BA in treating respiratory diseases. This review aims to summarize the current pharmacokinetics of BA, baicalin-loaded nano-delivery system, and its molecular mechanisms and therapeutical effects for treating respiratory diseases.Method: This review reviewed databases such as PubMed, NCBI, and Web of Science from their inception to 13 December 2022, in which literature was related to “baicalin”, “Scutellaria baicalensis Georgi”, “COVID-19”, “acute lung injury”, “pulmonary arterial hypertension”, “asthma”, “chronic obstructive pulmonary disease”, “pulmonary fibrosis”, “lung cancer”, “pharmacokinetics”, “liposomes”, “nano-emulsions”, “micelles”, “phospholipid complexes”, “solid dispersions”, “inclusion complexes”, and other terms.Result: The pharmacokinetics of BA involves mainly gastrointestinal hydrolysis, the enteroglycoside cycle, multiple metabolic pathways, and excretion in bile and urine. Due to the poor bioavailability and solubility of BA, liposomes, nano-emulsions, micelles, phospholipid complexes, solid dispersions, and inclusion complexes of BA have been developed to improve its bioavailability, lung targeting, and solubility. BA exerts potent effects mainly by mediating upstream oxidative stress, inflammation, apoptosis, and immune response pathways. It regulates are the NF-κB, PI3K/AKT, TGF-β/Smad, Nrf2/HO-1, and ERK/GSK3β pathways.Conclusion: This review presents comprehensive information on BA about pharmacokinetics, baicalin-loaded nano-delivery system, and its therapeutic effects and potential pharmacological mechanisms in respiratory diseases. The available studies suggest that BA has excellent possible treatment of respiratory diseases and is worthy of further investigation and development.

[1]  K. Takeda,et al.  Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer , 2022, PloS one.

[2]  F. Dahlke,et al.  Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence , 2022, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[3]  D. Glossman-Mitnik,et al.  Exploration of Anti-HIV Phytocompounds against SARS-CoV-2 Main Protease: Structure-Based Screening, Molecular Simulation, ADME Analysis and Conceptual DFT Studies , 2022, Molecules.

[4]  Kriengsak Lirdprapamongkol,et al.  PLGA-Lipid Hybrid Nanoparticles for Overcoming Paclitaxel Tolerance in Anoikis-Resistant Lung Cancer Cells , 2022, Molecules.

[5]  Mateusz Kciuk,et al.  Computational Bioprospecting Guggulsterone against ADP Ribose Phosphatase of SARS-CoV-2 , 2022, Molecules.

[6]  Chunling Xiao,et al.  Protective effect and mechanism of baicalin on lung inflammatory injury in BALB/cJ mice induced by PM2.5. , 2022, Ecotoxicology and environmental safety.

[7]  S. Uddin,et al.  Non-Invasive Biomarkers for Early Lung Cancer Detection , 2022, Cancers.

[8]  V. Novakovic,et al.  Pathophysiological mechanisms of thrombosis in acute and long COVID-19 , 2022, Frontiers in Immunology.

[9]  Fei Ye,et al.  Dysregulated hepatic UDP-glucuronosyltransferases and flavonoids glucuronidation in experimental colitis , 2022, Frontiers in Pharmacology.

[10]  Zhihong Wu,et al.  Baicalin prevents fibrosis of human trabecular meshwork cells via inhibiting the MyD88/NF-κB pathway. , 2022, European journal of pharmacology.

[11]  Xi-jun Wang,et al.  Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives , 2022, Cancers.

[12]  O. Sabzevari,et al.  Hybrid Ultrasound-Activated Nanoparticles Based on Graphene Quantum Dots for Cancer Treatment. , 2022, International journal of pharmaceutics.

[13]  Jia Hua Cheng,et al.  Development of Paeonol Liposomes: Design, Optimization, in vitro and in vivo Evaluation , 2022, International journal of nanomedicine.

[14]  D. Zorov,et al.  Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches , 2022, Antioxidants.

[15]  Z. Ye,et al.  Pharmacokinetics of baicalin and oroxyloside in plasma and different tissues of rats after transnasal aerosol inhalation and intravenous injection of Tanreqing , 2022, Frontiers in Pharmacology.

[16]  G. Floresta,et al.  An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022 , 2022, Molecules.

[17]  Q. Shi,et al.  Baicalin Inhibits Inflammation in Rats with Chronic Obstructive Pulmonary Disease by the TLR2/MYD88/NF-κBp65 Signaling Pathway , 2022, Evidence-based complementary and alternative medicine : eCAM.

[18]  A. Pandey,et al.  Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review , 2022, World journal of gastroenterology.

[19]  A. Salawi.  Self-emulsifying drug delivery systems: a novel approach to deliver drugs , 2022, Drug delivery.

[20]  Yun-Man Li,et al.  Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension , 2022, Molecules.

[21]  L. Wollin,et al.  BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis , 2022, Frontiers in Pharmacology.

[22]  Feng Feng,et al.  Baicalin inhibits inflammation of lipopolysaccharide-induced acute lung injury toll like receptor-4/myeloid differentiation primary response 88/nuclear factor-kappa B signaling pathway. , 2022, Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.

[23]  Weiming Xu,et al.  Liver-Targeted Nanoparticles Facilitate the Bioavailability and Anti-HBV Efficacy of Baicalin In Vitro and In Vivo , 2022, Biomedicines.

[24]  Jia You,et al.  Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm , 2022, Frontiers in Pharmacology.

[25]  Zhan-sheng Hu,et al.  Salidroside attenuates HALI via IL-17A-mediated ferroptosis of alveolar epithelial cells by regulating Act1-TRAF6-p38 MAPK pathway , 2022, Cell Communication and Signaling.

[26]  Xuan Zhou,et al.  Baicalin Inhibits EMT through PDK1/AKT Signaling in Human Nonsmall Cell Lung Cancer , 2021, Journal of oncology.

[27]  Ming Yang,et al.  Scutellaria baicalensis Extract-phospholipid Complex: Preparation and Initial Pharmacodynamics Research in Rats , 2021, Current pharmaceutical biotechnology.

[28]  N. Mohammadtursun,et al.  Baicalin ameliorates cigarette smoke-induced airway inflammation in rats by modulating HDAC2/NF-κB/PAI-1 signalling. , 2021, Pulmonary pharmacology & therapeutics.

[29]  D. Chen,et al.  Baicalein, Baicalin, and Wogonin: Protective Effects against Ischemia-Induced Neurodegeneration in the Brain and Retina , 2021, Oxidative medicine and cellular longevity.

[30]  Junguang Jiang,et al.  Baicalin alleviates chronic obstructive pulmonary disease through regulation of HSP72-mediated JNK pathway , 2021, Molecular medicine.

[31]  S. Sarafianos,et al.  Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase , 2021, Microorganisms.

[32]  M. Belvisi,et al.  Targeting Alveolar Repair in Idiopathic Pulmonary Fibrosis , 2021, American journal of respiratory cell and molecular biology.

[33]  Shuguang Huang,et al.  MNK as a potential pharmacological target for suppressing LPS-induced acute lung injury in mice , 2021, Biochemical Pharmacology.

[34]  Haiping Zhao,et al.  PBK/TOPK: A Therapeutic Target Worthy of Attention , 2021, Cells.

[35]  Shizhang Wei,et al.  Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. , 2021, Pharmacological research.

[36]  Wen Jiang,et al.  Protective effect of baicalin against pulmonary arterial hypertension vascular remodeling through regulation of TNF‐α signaling pathway , 2021, Pharmacology research & perspectives.

[37]  Qinggang Meng,et al.  A metabolomic approach to elucidate the inhibitory effects of baicalin in pulmonary fibrosis , 2021, Pharmaceutical biology.

[38]  Fucheng Zhao,et al.  Baicalin suppresses lung cancer growth phenotypes via miR-340-5p/NET1 axis , 2021, Bioengineered.

[39]  Xia Ding,et al.  Baicalin Induces Apoptosis and Suppresses the Cell Cycle Progression of Lung Cancer Cells Through Downregulating Akt/mTOR Signaling Pathway , 2021, Frontiers in Molecular Biosciences.

[40]  Yanfeng Wang,et al.  Hypoxia-Inducible Factor-1: A Potential Target to Treat Acute Lung Injury , 2020, Oxidative medicine and cellular longevity.

[41]  Qiyue Yang,et al.  Baicalin Liposome Alleviates Lipopolysaccharide-Induced Acute Lung Injury in Mice via Inhibiting TLR4/JNK/ERK/NF-κB Pathway , 2020, Mediators of inflammation.

[42]  Yi Qu,et al.  Regulatory Mechanisms of Baicalin in Cardiovascular Diseases: A Review , 2020, Frontiers in Pharmacology.

[43]  F. Zhang,et al.  Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms , 2020, Pharmacological Research.

[44]  J Zhang,et al.  LncRNA-AK149641 associated with airway inflammation in an OVA-induced asthma mouse model , 2020, Journal of Bioenergetics and Biomembranes.

[45]  W. Labaki,et al.  Chronic Obstructive Pulmonary Disease , 2020, Annals of Internal Medicine.

[46]  L. Q. Quintans Júnior,et al.  The use of cyclodextrin inclusion complexes to improve anticancer drug profiles: a systematic review , 2020, Expert opinion on drug delivery.

[47]  C. Cho,et al.  Development and Evaluation of Docetaxel-Phospholipid Complex Loaded Self-Microemulsifying Drug Delivery System: Optimization and In Vitro/Ex Vivo Studies , 2020, Pharmaceutics.

[48]  J. Kou,et al.  Baicalin combats glutamate excitotoxicity via protecting glutamine synthetase from ROS-induced 20S proteasomal degradation , 2020, Redox biology.

[49]  Raju C Reddy,et al.  Bidirectional interaction of airway epithelial remodeling and inflammation in asthma. , 2020, Clinical science.

[50]  J. Flynn,et al.  ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic , 2020, Hypertension.

[51]  Y. Nishimura,et al.  Group 2 Innate Lymphoid Cells and the House Dust Mite-Induced Asthma Mouse Model , 2020, Cells.

[52]  Zhenhua Li,et al.  Baicalin alleviates bleomycin-induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K/AKT signaling pathway , 2020, Molecular medicine reports.

[53]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[54]  Fangdi Hu,et al.  The metabolic effect of gut microbiota on drugs , 2020, Drug metabolism reviews.

[55]  C. Yuan,et al.  Baicalein, an enteric microbial metabolite, suppresses gut inflammation and cancer progression in ApcMin/+ mice , 2019, Clinical and Translational Oncology.

[56]  B. King-Kallimanis,et al.  US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017. , 2019, The Lancet. Oncology.

[57]  Jinxia Wang,et al.  Baicalin prevents pulmonary arterial remodeling in vivo via the AKT/ERK/NF-κB signaling pathways , 2019, Pulmonary circulation.

[58]  Xiangli Meng,et al.  Baicalin ameliorates lipopolysaccharide-induced acute lung injury in mice by suppressing oxidative stress and inflammation via the activation of the Nrf2-mediated HO-1 signaling pathway , 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

[59]  Ji-cheng Tantai,et al.  Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7 , 2019, Cell death & disease.

[60]  Peng-Fei Yi,et al.  Baicalin alleviated APEC-induced acute lung injury in chicken by inhibiting NF-κB pathway activation. , 2019, International immunopharmacology.

[61]  Jiahao Huang,et al.  Investigating the Phospholipid Effect on the Bioaccessibility of Rosmarinic Acid-Phospholipid Complex through a Dynamic Gastrointestinal in Vitro Model , 2019, Pharmaceutics.

[62]  Xin Diao,et al.  Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase , 2019, Bioscience reports.

[63]  W. Yao,et al.  Baicalin mitigates cognitive impairment and protects neurons from microglia‐mediated neuroinflammation via suppressing NLRP3 inflammasomes and TLR4/NF‐κB signaling pathway , 2019, CNS neuroscience & therapeutics.

[64]  X. Hou,et al.  Development of dual-targeted nano-dandelion based on an oligomeric hyaluronic acid polymer targeting tumor-associated macrophages for combination therapy of non-small cell lung cancer , 2019, Drug delivery.

[65]  In-Soo Yoon,et al.  Preparation, Characterization, and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin , 2018, Pharmaceutics.

[66]  Wei Zhang,et al.  Astragaloside IV modulates TGF‐β1‐dependent epithelial‐mesenchymal transition in bleomycin‐induced pulmonary fibrosis , 2018, Journal of cellular and molecular medicine.

[67]  M. Haider,et al.  Thermogelling Platform for Baicalin Delivery for Versatile Biomedical Applications. , 2018, Molecular pharmaceutics.

[68]  Jinghua Peng,et al.  Baicalin, a Chinese Herbal Medicine, Inhibits the Proliferation and Migration of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells, A549 and H1299, by Activating the SIRT1/AMPK Signaling Pathway , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[69]  Linghao Qin,et al.  Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug. , 2018, Molecular pharmaceutics.

[70]  Hongfei Wu,et al.  Formulation optimization and the absorption mechanisms of nanoemulsion in improving baicalin oral exposure , 2018, Drug development and industrial pharmacy.

[71]  J. Ryu,et al.  Current Concepts in Pathogenesis, Diagnosis, and Management of Smoking‐Related Interstitial Lung Diseases , 2017, Chest.

[72]  Bin Zhou,et al.  Baicalin potentiates TRAIL‑induced apoptosis through p38 MAPK activation and intracellular reactive oxygen species production. , 2017, Molecular medicine reports.

[73]  Jinhua Lu,et al.  Baicalin alleviates radiation-induced epithelial-mesenchymal transition of primary type II alveolar epithelial cells via TGF-β and ERK/GSK3β signaling pathways. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[74]  Xuemei Zhang,et al.  Regulatory effect of baicalin on the imbalance of Th17/Treg responses in mice with allergic asthma. , 2017, Journal of ethnopharmacology.

[75]  Liangxing Wang,et al.  Baicalin attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2A receptor-induced SDF-1/CXCR4/PI3K/AKT signaling , 2017, Journal of Biomedical Science.

[76]  R. Sharif.  Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. , 2017, The American journal of managed care.

[77]  P. Deng,et al.  The formation of a host‐guest inclusion complex system between β‐cyclodextrin and baicalin and its dissolution characteristics , 2017, The Journal of pharmacy and pharmacology.

[78]  H. Walczak,et al.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy , 2017, Nature Reviews Cancer.

[79]  I. Adcock,et al.  Animal models of COPD: What do they tell us? , 2017, Respirology.

[80]  Yonggen Zou,et al.  Lung-targeting drug delivery system of baicalin-loaded nanoliposomes: development, biodistribution in rabbits, and pharmacodynamics in nude mice bearing orthotopic human lung cancer , 2016, International journal of nanomedicine.

[81]  Zhi-wei Xu,et al.  Baicalin attenuates DDP (cisplatin) resistance in lung cancer by downregulating MARK2 and p-Akt. , 2017, International journal of oncology.

[82]  F. Liu,et al.  Baicalin attenuates inflammation in mice with OVA-induced asthma by inhibiting NF-κB and suppressing CCR7/CCL19/CCL21. , 2016, International journal of molecular medicine.

[83]  Jie Song,et al.  Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion , 2016, Pharmacognosy magazine.

[84]  Yicheng He,et al.  Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF-β1-induced ERK1/2 signaling pathway , 2016, BMC Pulmonary Medicine.

[85]  Liangxing Wang,et al.  Baicalin Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension to Improve Hypoxic Cor Pulmonale by Reducing the Activity of the p38 MAPK Signaling Pathway and MMP-9 , 2016, Evidence-based complementary and alternative medicine : eCAM.

[86]  L. Minh,et al.  Baicalin loaded in folate-PEG modified liposomes for enhanced stability and tumor targeting. , 2016, Colloids and surfaces. B, Biointerfaces.

[87]  Yonggen Zou,et al.  LC-UV Determination of Baicalin in Rabbit Plasma and Tissues for Application in Pharmacokinetics and Tissue Distribution Studies of Baicalin after Intravenous Administration of Liposomal and Injectable Formulations , 2016, Molecules.

[88]  Yongmun Choi,et al.  Identification and Characterization of Baicalin as a Phosphodiesterase 4 Inhibitor , 2016, Phytotherapy research : PTR.

[89]  G. Zhai,et al.  In vitro and in vivo study of Baicalin-loaded mixed micelles for oral delivery , 2015, Drug delivery.

[90]  D. Weng,et al.  Baicalin Alleviates Silica-Induced Lung Inflammation and Fibrosis by Inhibiting the Th17 Response in C57BL/6 Mice. , 2015, Journal of natural products.

[91]  Y. Park,et al.  Baseline Characteristics of the Korean Registry of Pulmonary Arterial Hypertension , 2015, Journal of Korean medical science.

[92]  Jiyang Xu,et al.  Baicalin attenuates angiotensin II-induced endothelial dysfunction. , 2015, Biochemical and biophysical research communications.

[93]  N. Wheate,et al.  The state-of-play and future of platinum drugs. , 2015, Endocrine-related cancer.

[94]  S. Chao,et al.  Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response. , 2015, International immunopharmacology.

[95]  Yanjiang Qiao,et al.  Profiling and identification of the metabolites of baicalin and study on their tissue distribution in rats by ultra-high-performance liquid chromatography with linear ion trap-Orbitrap mass spectrometer. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[96]  Q. Hamid,et al.  Upregulation of IL-17A/F from human lung tissue explants with cigarette smoke exposure: implications for COPD , 2014, Respiratory Research.

[97]  J. Olin,et al.  Asthma: pathogenesis and novel drugs for treatment , 2014, BMJ : British Medical Journal.

[98]  G. Zhai,et al.  Preparation, optimization, characterization and cytotoxicity in vitro of Baicalin-loaded mixed micelles. , 2014, Journal of colloid and interface science.

[99]  Jun Wu,et al.  Preparation, pharmacokinetics and biodistribution of baicalin-loaded liposomes , 2014, International journal of nanomedicine.

[100]  B. Liu,et al.  Downregulation of miR‐638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC , 2014, FEBS letters.

[101]  Xiaoling Li,et al.  Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin , 2014, Acta pharmaceutica Sinica. B.

[102]  P. Barnes.  Cellular and molecular mechanisms of chronic obstructive pulmonary disease. , 2014, Clinics in chest medicine.

[103]  T. Allen,et al.  Interleukin 8 and acute lung injury. , 2014, Archives of pathology & laboratory medicine.

[104]  Shiping Ma,et al.  Anti‐asthmatic Effects of Baicalin in a Mouse Model of Allergic Asthma , 2014, Phytotherapy research : PTR.

[105]  Bo-wen Wang,et al.  Dissolution and pharmacokinetics of baicalin–polyvinylpyrrolidone coprecipitate , 2013, The Journal of pharmacy and pharmacology.

[106]  Hong Shen,et al.  PBK/TOPK expression in non‐small‐cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression , 2013, Histopathology.

[107]  Junjiang Fu,et al.  Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation , 2013, International journal of nanomedicine.

[108]  Hongtao Zhao,et al.  Biotransformation of baicalin to baicalein significantly strengthens the inhibition potential towards UDP-glucuronosyltransferases (UGTs) isoforms. , 2013, Die Pharmazie.

[109]  Weifeng Zhu,et al.  Process optimization and evaluation of novel baicalin solid nanocrystals , 2013, International journal of nanomedicine.

[110]  M. Hattori,et al.  Baicalein 6-O-β-D-glucopyranuronoside is a main metabolite in the plasma after oral administration of baicalin, a flavone glucuronide of scutellariae radix, to rats. , 2013, Biological & pharmaceutical bulletin.

[111]  Q. Luo,et al.  Effects of Baicalin on Airway Remodeling in Asthmatic Mice , 2013, Planta Medica.

[112]  Moisés Selman,et al.  Idiopathic pulmonary fibrosis , 2011, The Lancet.

[113]  Baojun Liu,et al.  Baicalin attenuates inflammation by inhibiting NF-kappaB activation in cigarette smoke induced inflammatory models. , 2010, Pulmonary pharmacology & therapeutics.

[114]  Xiaofei Shang,et al.  The genus Scutellaria an ethnopharmacological and phytochemical review. , 2010, Journal of ethnopharmacology.

[115]  M. Lehner,et al.  PDE4 inhibitors: a review of current developments (2005 – 2009) , 2009, Expert opinion on therapeutic patents.

[116]  Jianbin Chao,et al.  Preparation and characterization of the inclusion complex of Baicalin (BG) with beta-CD and HP-beta-CD in solution: an antioxidant ability study. , 2009, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[117]  Shu-Yu Wu,et al.  Baicalin attenuates air embolism‐induced acute lung injury in rat isolated lungs , 2009, British journal of pharmacology.

[118]  B. Sarmento,et al.  Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. , 2007, Drug discovery today.

[119]  Anindya Dutta,et al.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. , 2007, Genes & development.

[120]  Guangji Wang,et al.  Comparative pharmacokinetics of baicalin after oral administration of pure baicalin, Radix scutellariae extract and Huang-Lian-Jie-Du-Tang to rats. , 2007, Journal of ethnopharmacology.

[121]  N. Venkatesan,et al.  Protection from acute and chronic lung diseases by curcumin. , 2007, Advances in experimental medicine and biology.

[122]  Z. Zuo,et al.  Involvement of UDP-Glucuronosyltransferases in the Extensive Liver and Intestinal First-Pass Metabolism of Flavonoid Baicalein , 2006, Pharmaceutical Research.

[123]  Li Taiming,et al.  Investigation of the absorption mechanisms of baicalin and baicalein in rats. , 2006, Journal of pharmaceutical sciences.

[124]  Marie-Hélène Dufresne,et al.  Block copolymer micelles: preparation, characterization and application in drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[125]  J. Xing,et al.  Absorption and enterohepatic circulation of baicalin in rats. , 2005, Life sciences.

[126]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[127]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[128]  M. Ishihara,et al.  [Combination use of kampo-medicines and drugs affecting intestinal bacterial flora]. , 2002, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[129]  K. Kobashi,et al.  Balicalin, the Predominant Flavone Glucuronide of Scutellariae Radix, is Absorbed from the Rat Gastrointestinal Tract as the Aglycone and Restored to its Original Form , 2000, The Journal of pharmacy and pharmacology.